Key Details
The amendment expands India’s QR code-based medicine authentication system from selected pharmaceutical brands to entire categories of high-risk medicines, improving traceability across the supply chain.
What has changed? | Implication |
|---|---|
Vaccines, antimicrobials, anti-cancer medicines and NDPS drugs are included under Schedule H2 | Extends digital traceability to medicines with significant public-health and regulatory importance |
QR code or barcode mandatory on primary or secondary packaging | Enables authentication throughout the distribution chain |
Digital codes must carry manufacturing, batch and licence information | Improves product verification and recall capability |
Implementation will be phased | Vaccines, anti-cancer and NDPS drugs from 1 July 2027; antimicrobials from 1 July 2028 |
Summary
India Is Expanding Digital Drug Traceability
India has amended the Drugs Rules, 1945 to significantly widen the scope of its pharmaceutical track-and-trace framework. Until now, QR code-based authentication primarily covered the country’s top 300 pharmaceutical brands. The new amendment extends the requirement to entire categories of medicines that carry higher public-health or regulatory risks.
From Product Authentication to Supply-Chain Integrity
Manufacturers will be required to place QR codes or barcodes on eligible medicines, allowing regulators, distributors, healthcare providers and consumers to verify essential information such as product identity, batch number, manufacturing details and expiry dates. The measure aims to improve product authentication while making it easier to detect counterfeit, diverted or substandard medicines.
Different Medicine Categories Serve Different Policy Goals
The expanded framework supports multiple regulatory objectives:
Vaccines: strengthen confidence in immunisation supply chains.
Anti-cancer medicines: improve authenticity of high-value therapies vulnerable to counterfeiting.
Antimicrobials: reinforce efforts to combat antimicrobial resistance by improving oversight of medicine quality.
Narcotic and psychotropic medicines: strengthen monitoring of legitimate medical use while reducing diversion and misuse.
A Phased Transition for Industry
Recognising the operational changes required across pharmaceutical manufacturing and distribution, the notification adopts a phased implementation schedule. Requirements for vaccines, anti-cancer medicines and NDPS drugs will take effect from 1 July 2027, while antimicrobials will be covered from 1 July 2028, allowing industry time to upgrade packaging and traceability systems.
What is Schedule H2?
Schedule H2 under the Drugs Rules, 1945 requires specified medicines to carry barcode or QR code-based identification, enabling their authentication and traceability across the pharmaceutical supply chain. The framework helps regulators combat counterfeit medicines while strengthening product quality oversight.
Policy Relevance
Expands India’s digital pharmaceutical traceability system beyond selected brands to high-risk therapeutic categories.
Strengthens the fight against counterfeit and substandard medicines by improving authentication throughout the supply chain.
Supports the National Action Plan on Antimicrobial Resistance through better monitoring of antimicrobial medicines.
Improves regulatory oversight of vaccines, anti-cancer medicines and controlled substances, where product integrity is critical.
Reinforces India’s move towards technology-enabled pharmaceutical regulation, combining digital verification with supply-chain transparency.
Creates a stronger foundation for future end-to-end medicine traceability, recalls and post-market surveillance.
Relevant Question for Policy Stakeholders: How can India extend QR code-based traceability beyond authentication to create an interoperable, end-to-end pharmaceutical track-and-trace system covering manufacturing, distribution, dispensing and post-market surveillance?
Follow the Full Notification Here: Union Health Ministry Expands QR Code-Based Drug Traceability Framework